NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis S.A. Annual General Meeting (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in Paris, at its head office.
At the meeting, during which more than 64% of voting rights were exercised, all the resolutions for which the management recommended a vote in favor, were adopted.
The resolutions adopted by Cellectis' shareholders included notably:
- Approval of the annual financial statements for the financial year ended December 31, 2017;
- Approval of the consolidated financial statements for the financial year ended December 31, 2017.
- Renewal of the term of office of Director of Mr. André Choulika, Mr. David Sourdive and Mr. Alain Godard;
- Renewal of the term office of Ernst & Young et Autres, and J.M.H. Conseil as Company’s Statutory Auditors.
The full results of the vote can be examined on the company’s website www.cellectis.com/en/investors/general-meetings/
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by Cellectis.